{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009649","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.045451+00:00","generated_at":"2026-05-16T10:49:30.863840+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kura Oncology reports $2.1M KOMZIFTI net revenue in first 5 weeks post-launch; cash at $667M","bullets":["$2.1M KOMZIFTI net product revenue from Nov 21 to Dec 31, 2025 (first commercial sales).","$195M milestone payment from Kyowa Kirin in Q4 2025; non-cash collaboration revenue $15-17M.","Cash, cash equivalents & short-term investments $667.3M as of Dec 31, 2025.","KOMZIFTI granted full FDA approval in Nov 2025 for R/R NPM1-mutated AML; NCCN Category 2A.","2026 guidance: non-cash collaboration revenue $45-55M; pipeline milestones include Phase 3 trial enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009649","json":"https://secwatch.observer/filing/0001193125-26-009649.json","markdown":"https://secwatch.observer/filing/0001193125-26-009649.md","text":"https://secwatch.observer/filing/0001193125-26-009649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526009649/0001193125-26-009649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526009649/d55582d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:49:30.863840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}